Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.
Phase of Trial: Phase I
Latest Information Update: 18 May 2015
At a glance
- Drugs PLX PAD (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors Pluristem Therapeutics
- 18 May 2015 According to a Pluristem Therapeutics media release, the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency's Adaptive Pathways pilot project.
- 27 Nov 2014 New trial record